Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.
Department of Population Health Sciences, Weill Cornell Medical College, New York, NY, USA.
Drug Alcohol Depend. 2020 Oct 1;215:108221. doi: 10.1016/j.drugalcdep.2020.108221. Epub 2020 Aug 5.
To examine the health-related quality-of-life (HRQoL) of persons with opioid use disorder (OUD) seeking treatment in an inpatient detoxification or short-term residential setting; continuing treatment as outpatients.
We conducted a secondary analysis of data from a clinical trial (N = 508) where participants were randomized to extended-release naltrexone or buprenorphine-naloxone for the prevention of opioid relapse. We used a generalized structural equation regression mixture model to identify associations of HRQoL (EQ-5D) trajectories, including latent characteristics, over the 24-week trial and 36-week follow-up period, among participants who reported HRQoL beyond baseline. This novel framework accounted for baseline and time-varying characteristics, while simultaneously identifying latent classes.
We identified two subpopulations: HRQoL "pharmacotherapy responsive" (82.3 %) and HRQoL "characteristic sensitive" (17.7 %). The pharmacotherapy responsive subpopulation was characterized by a shortterm HRQoL improvement and then stable HRQoL over time, and by a positive association between HRQoL and receiving pharmacotherapy in the past 30 days. The characteristic sensitive subpopulation was characterized by an initial improvement in HRQoL with a gradual decline over time, and no significant HRQoL response to pharmacotherapy. HRQoL changes over time in this subpopulation were more influenced by baseline demographic, socioeconomic, and psychosocial characteristics.
Our findings suggest that while HRQoL may be improved and sustained through targeted efforts to promote use of pharmacotherapy for many persons with OUD, an identifiable subpopulation may require additional services that address socioeconomic and psychosocial issues to achieve HRQoL benefits. Our analysis provides insight for improving individualized care for persons with opioid use disorder seeking treatment.
考察在住院戒毒或短期住院治疗环境中寻求治疗的阿片类药物使用障碍(OUD)患者的健康相关生活质量(HRQoL);继续接受门诊治疗。
我们对一项临床试验(N=508)的数据进行了二次分析,其中参与者被随机分配接受缓释纳曲酮或丁丙诺啡-纳洛酮预防阿片类药物复发。我们使用广义结构方程回归混合模型来识别 HRQoL(EQ-5D)轨迹的关联,包括潜在特征,在 24 周试验和 36 周随访期间,在报告基线后 HRQoL 的参与者中。这种新的框架考虑了基线和时变特征,同时识别潜在类别。
我们确定了两个亚人群:HRQoL“药物治疗反应良好”(82.3%)和 HRQoL“特征敏感”(17.7%)。药物治疗反应良好的亚人群表现为短期 HRQoL 改善,然后随着时间的推移 HRQoL 稳定,并且过去 30 天内接受药物治疗与 HRQoL 呈正相关。特征敏感的亚人群表现为 HRQoL 最初改善,随着时间的推移逐渐下降,并且对药物治疗没有明显的 HRQoL 反应。在该亚人群中,HRQoL 随时间的变化更多地受到基线人口统计学、社会经济和心理社会特征的影响。
我们的研究结果表明,虽然通过有针对性地努力促进许多 OUD 患者使用药物治疗可以提高和维持 HRQoL,但可识别的亚人群可能需要解决社会经济和心理社会问题的额外服务,以实现 HRQoL 获益。我们的分析为改善寻求治疗的阿片类药物使用障碍患者的个体化护理提供了思路。